Health Care/Hospital

Innovent Delivers Oral Presentation on Phase 1 Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Advanced Non-small Cell Lung Cancer at the 2024 WCLC

SAN FRANCISCO and SUZHOU, China, Sept. 11, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metaboli...

2024-09-11 08:00 2050

'Highly Accurate': Telix's Phase III ZIRCON Trial for Kidney Cancer Imaging Published in The Lancet Oncology

MELBOURNE, Australia, Sept. 11, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that primary results from its Phase III ZIRCON[1] trial have been published in The Lancet Oncology, reporting that Telix's first-in-class investigational PET[2] agent,...

2024-09-11 06:46 1526

SOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing

The companies commit to bring cutting-edge liquid biopsy testing to 20 institutions globally over the next 12 months BOSTON and ROLLE, Switzerland, Sept. 10, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medic...

2024-09-10 22:50 1351

LifeSpan Vision Ventures Invests in Remedium Bio

NORWALK, Conn., Sept. 10, 2024 /PRNewswire/ -- LifeSpan Vision Ventures today announced that it has closed an investment in Remedium Bio.   - The biotechnology company is developing a first-in-class adjus...

2024-09-10 22:17 1247

Study Shows Ubie Symptom Checker Accuracy Rivals Physicians, Outperforms Competitors In Providing Disease Information

* Results show Ubie's differential diagnosis platform had a Top-5 hit accuracy of 63.4% and a Top-10 hit accuracy of 71.6%; median physician accuracy was 72.9% * Ubie is effective in providing relevant information based on symptoms, making it valuable in speeding diagnosis and care delivery f...

2024-09-10 21:30 1092

Lunit to Present AI-Analyzed Immune Phenotype Study as Immunotherapy Response Predictor for Advanced Gastric Cancer at ESMO Congress 2024

* Lunit SCOPE IO® demonstrates potential to assess immune phenotype as an AI-powered biomarker for predicting efficacy of Nivolumab plus Chemotherapy in advanced gastric cancer, independent of PD-L1 status SEOUL, South Korea, Sept. 10, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provi...

2024-09-10 21:00 1633

IMG Shares Top International Destinations for Autumn 2024

* IMG took a sample of its customers and reviewed more than 40,000 travel itineraries of members with upcoming travel plans betweenSeptember 1st and November 30th of 2024 to determine emerging travel trends this autumn. INDIANAPOLIS, Sept. 10, 2024 /PRNewswire/ -- IMG (International Medical Gro...

2024-09-10 21:00 1251

Ractigen Announces Positive Clinical Data for RAG-17 in ALS-SOD1 Treatment from Investigator-Initiated Trial

NANTONG, China and SUZHOU, China, Sept. 10, 2024 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing innovative therapies, today announced promising clinical data from an Investigator-Initiated Trial (IIT) of RAG-17, a small interfering RNA (siRN...

2024-09-10 20:00 1459

Lakeshore Biopharma to Hold an Extraordinary General Meeting of Shareholders on September 27, 2024

GAITHERSBURG, Md., Sept. 10, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for ...

2024-09-10 20:00 3138

I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer

- Pharmacokinetic/pharmacodynamic (PK/PD) modeling data from three Phase 1 studies providing dosing support for upcoming clinical trials - Exposure-Response (E-R) Analysis showed a positive correlation between uliledlimab concentration and ORR probability in mNSCLC patients - Randomized Phase 2 st...

2024-09-10 19:00 1011

The 2024 International (Bozhou) TCM Expo Kicked Off

BOZHOU, China, Sept. 10, 2024 /PRNewswire/ -- On the morning of September 9, the 2024 International (Bozhou) TCM Expo and the 40th National (Bozhou) TCM Trade Fair officially kicked off in Bozhou,Anhui Province. In recent years, Bozhou has been enhancing mechanisms for the inheritance, innovatio...

2024-09-10 17:55 920

RingConn Showcases Gen 2 Smart Ring at IFA 2024: Revolutionizing Sleep Monitoring with Integrated Sleep Apnea Detection

BERLIN, Sept. 10, 2024 /PRNewswire/ -- RingConn , a leading personal health technology company, recently showcased its newest innovation—the RingConn Gen 2 Smart Ring—at IFA 2024. This groundbreaking device is the first smart ring to feature integrated sleep ...

2024-09-10 15:00 1512

ICP DAS-BMP Reveals Advanced Engineering TPUs at Medtec China 2024

HSINCHU, Sept. 10, 2024 /PRNewswire/ -- ICP DAS-BMP (Biomedical Polymers), a Taiwan-based medical TPU (thermoplastic polyurethane) manufacturer and supplier, is excited to announce its participation in Medtec China 2024. The 18th edition of this exhibition will be held fromSeptember 25-27, 202...

2024-09-10 09:30 1809

Innovent Delivers Oral Presentation of Updated Results from a Pivotal Phase 2 Study of Dupert® (Fulzerasib) in Patients with Advanced Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation

SAN FRANCISCO and SUZHOU, China, Sept. 10, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmun...

2024-09-10 08:00 2205

IonOpticks partners with Adelis to accelerate global expansion and innovation

IonOpticks responds to growing global market needs for proteomics tools by partnering with Nordic private equity firm MELBOURNE, Australia and STOCKHOLM, Sept. 10, 2024 /PRNewswire/ -- IonOpticks , a leading global producer of high-performance chromatography columns, ann...

2024-09-10 06:00 1624

PATH Appoints Dr Bilal Mateen as Inaugural Chief AI Officer

SEATTLE, Sept. 10, 2024 /PRNewswire/ -- PATH, a global nonprofit dedicated to achieving health equity, today announced the appointment ofBilal Mateen as its Chief AI Officer. In this newly created role, Mateen will lead PATH's efforts to harness the power of artificial intelligence (AI) to accele...

2024-09-10 05:16 1269

Seegene Expands mpox RUO Product Lineups with Enhanced Detection Assays for Clade 1

* Introduces Novaplex™ MPXV/OPXV plus Assay (RUO) that is designed to detect Clade I, which has higher transmission and mortality rates than Clade II * Adheres to the WHO issued target product profiles and provides accurate detection of viral strains * Offers healthcare professionals with ...

2024-09-09 22:15 2176

Xiao-I Corporation and the National Association of the Deaf Partner to Enhance Accessible Communication for Deaf Individuals with AI Technology

SHANGHAI, Sept. 9, 2024 /PRNewswire/ -- Xiao-I Corporation (NASDAQ: AIXI) ("Xiao-I" or the "Company"), a leading artificial intelligence company, announces that it signed a strategic partnership with the National Association of the Deaf (the "NAD"), a premier American organization dedicated to im...

2024-09-09 21:45 1801

Bambusa Therapeutics Inc. Announces Successful Series Seed Funding to Advance Innovative Bispecific Antibodies for Immunology & Inflammation

BOSTON, Sept. 9, 2024 /PRNewswire/ -- Bambusa Therapeutics Inc., a biotechnology company focused on developing bispecific antibodies for the treatment of immunological and inflammatory (I&I) disorders, announced the successful closing of its Series Seed financing round, raising approximately$15 ...

2024-09-09 21:09 1206

Lunit Joins Roche's Digital Pathology Open Environment to Advance Cancer Biomarker Testing

* Lunit's AI-powered biomarker, Lunit SCOPE PD-L1 TPS, integrates into Roche's navify® Digital Pathology platform to enhance precision medicine and improve cancer biomarker testing SEOUL, South Korea, Sept. 9, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solution...

2024-09-09 21:00 1463
1 ... 65666768697071 ... 859